US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
CA2222545A1
(fr)
*
|
1995-06-07 |
1996-12-19 |
Sugen, Inc. |
Quinazolines et compositions pharmaceutiques
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6147106A
(en)
*
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
JP4713698B2
(ja)
|
1997-03-05 |
2011-06-29 |
スージェン, インク. |
疎水性薬剤の処方
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
US6051593A
(en)
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
TR200003514T2
(tr)
|
1998-05-29 |
2002-05-21 |
Sugen Inc. |
Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
|
EP1149093A1
(fr)
|
1998-12-17 |
2001-10-31 |
F. Hoffmann-La Roche Ag |
4-aryloxindoles utilises comme inhibiteurs de proteines kinases jnk
|
JP2002532492A
(ja)
|
1998-12-17 |
2002-10-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
サイクリン−依存性キナーゼ、特にcdk2のインヒビターとしての4−アルケニル(及びアルキニル)オキシドール
|
WO2000035921A1
(fr)
|
1998-12-17 |
2000-06-22 |
F. Hoffmann-La Roche Ag |
4,5-pyrazinoxindoles comme inhibiteurs de proteine kinase
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
JP2002540096A
(ja)
*
|
1999-03-24 |
2002-11-26 |
スージェン・インコーポレーテッド |
キナーゼ阻害剤としてのインドリノン化合物
|
JP2000281588A
(ja)
*
|
1999-03-30 |
2000-10-10 |
Sankyo Co Ltd |
ガンの予防又は治療薬及びそのスクリーニング方法
|
AU4556800A
(en)
*
|
1999-04-27 |
2000-11-10 |
Smithkline Beecham Plc |
Novel treatment
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
MXPA02006263A
(es)
|
1999-12-22 |
2004-02-26 |
Sugen Inc |
Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona.
|
US6339100B1
(en)
*
|
1999-12-29 |
2002-01-15 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting mastocytosis
|
WO2001056557A2
(fr)
*
|
2000-02-05 |
2001-08-09 |
Vertex Pharmaceuticals Incorporated |
Compositions utiles comme inhibiteurs de erk
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
TWI270545B
(en)
|
2000-05-24 |
2007-01-11 |
Sugen Inc |
Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
AU2001268154A1
(en)
|
2000-06-02 |
2001-12-17 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
US7427689B2
(en)
*
|
2000-07-28 |
2008-09-23 |
Georgetown University |
ErbB-2 selective small molecule kinase inhibitors
|
AU2001271611A1
(en)
*
|
2000-09-01 |
2002-03-22 |
Glaxo Group Limited |
Oxindole derivatives
|
US6638965B2
(en)
|
2000-11-01 |
2003-10-28 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
|
DE10054019A1
(de)
*
|
2000-11-01 |
2002-05-23 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
EP1488809A1
(fr)
|
2001-01-16 |
2004-12-22 |
Glaxo Group Limited |
combinaison pharmaceutique contenant de l'amino-4 quinazoline et un autre agent antineoplasique pour le traitement du cancer
|
JP2004529110A
(ja)
|
2001-03-06 |
2004-09-24 |
アストラゼネカ アクチボラグ |
脈管損傷活性を有するインドール誘導体
|
AU2002303892A1
(en)
|
2001-05-30 |
2002-12-09 |
Jingrong Cui |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
DE10134196B4
(de)
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
ES2275021T3
(es)
*
|
2001-09-27 |
2007-06-01 |
Smithkline Beecham Corporation |
Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico.
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US20030119839A1
(en)
*
|
2001-12-13 |
2003-06-26 |
Nan-Horng Lin |
Protein kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
GB0206861D0
(en)
*
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Medicaments
|
WO2003084951A1
(fr)
*
|
2002-04-03 |
2003-10-16 |
Allergan, Inc. |
(3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones utilisees en tant qu'inhibiteurs de kinases
|
US6541504B1
(en)
*
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
JP2005534623A
(ja)
*
|
2002-04-08 |
2005-11-17 |
スミスクライン ビーチャム コーポレーション |
Erbファミリーの阻害剤並びにraf及び/又はras阻害剤を投与することを含む癌の治療法
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
US7585866B2
(en)
*
|
2002-07-31 |
2009-09-08 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
US7470709B2
(en)
*
|
2002-08-23 |
2008-12-30 |
Novartis Vaccines And Diagnostics, Inc. |
Benzimidazole quinolinones and uses thereof
|
US8673924B2
(en)
|
2002-09-04 |
2014-03-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
PL224879B1
(pl)
|
2002-09-04 |
2017-02-28 |
Pharmacopeia Drug Discovery Inc |
Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
|
DE60318089T2
(de)
*
|
2002-10-09 |
2008-12-04 |
Critical Outcome Technologies, Inc. |
Protein-tyrosine-kinase-inhibitoren
|
JP2006511616A
(ja)
*
|
2002-11-13 |
2006-04-06 |
カイロン コーポレイション |
癌の処置方法およびその関連方法
|
AU2003302665B2
(en)
*
|
2002-11-15 |
2009-12-24 |
Symphony Evolution, Inc. |
Kinase modulators
|
US20050019366A1
(en)
*
|
2002-12-31 |
2005-01-27 |
Zeldis Jerome B. |
Drug-coated stents and methods of use therefor
|
WO2004064733A2
(fr)
*
|
2003-01-15 |
2004-08-05 |
Board Of Regents, University Of Texas System |
Utilisation d'inhibiteurs de c-raf dans le traitement de maladies neurodegeneratives
|
JP4776537B2
(ja)
|
2003-05-27 |
2011-09-21 |
ロベルト・ペール・ヘーガークヴィスト |
糖尿病処置のためのチロシンキナーゼ阻害剤の使用
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
DE602004021838D1
(de)
*
|
2003-10-16 |
2009-08-13 |
Novartis Vaccines & Diagnostic |
Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
|
JP4890255B2
(ja)
*
|
2003-11-07 |
2012-03-07 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
|
WO2005068424A1
(fr)
*
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Derives d'indolinone en tant qu'inhibiteurs de tyrosine kinase de recepteurs
|
EP1719771A1
(fr)
*
|
2004-02-19 |
2006-11-08 |
Takeda Pharmaceutical Company Limited |
D rive de pyrazoloquinolone et utilisation de celui-ci
|
US7875624B2
(en)
*
|
2004-02-20 |
2011-01-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulating and measuring cellular adhesion
|
DE102004012070A1
(de)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
|
NZ561215A
(en)
|
2005-02-22 |
2010-12-24 |
Univ Michigan |
Small molecule inhibitors of MDM2 and uses thereof
|
KR101319122B1
(ko)
*
|
2005-05-13 |
2013-10-23 |
노파르티스 아게 |
약물 저항성 암을 치료하는 방법
|
MX2007014782A
(es)
|
2005-05-23 |
2008-02-19 |
Novartis Ag |
Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
|
TWI387592B
(zh)
*
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
PL1957074T3
(pl)
*
|
2005-11-29 |
2014-08-29 |
Novartis Ag |
Preparaty chinolinonów
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
ATE485268T1
(de)
|
2006-02-16 |
2010-11-15 |
Schering Corp |
Pyrrolidin-derivate als erk-hemmer
|
CN101516335B
(zh)
*
|
2006-07-21 |
2014-01-08 |
诺瓦提斯公司 |
苯并咪唑基吡啶基醚的制剂
|
US20100004253A1
(en)
*
|
2006-09-19 |
2010-01-07 |
Novartis Ag |
Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
|
CA2673683C
(fr)
|
2007-01-11 |
2014-07-29 |
Critical Outcome Technologies, Inc. |
Composes et methode de traitement un cancer
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
US20110160130A1
(en)
*
|
2007-02-16 |
2011-06-30 |
Connie Erickson-Miller |
Cancer treatment method
|
US20110129550A1
(en)
*
|
2007-02-16 |
2011-06-02 |
Connie Erickson-Miller |
Cancer treatment method
|
UY30915A1
(es)
|
2007-02-16 |
2008-09-02 |
Smithkline Beecham Corp |
Método de tratamiento de canceres
|
WO2008134124A1
(fr)
*
|
2007-04-30 |
2008-11-06 |
The Uab Research Foundation |
Inhibiteurs de ul97 utilisés pour traiter des troubles prolifératifs
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
CL2008001626A1
(es)
|
2007-06-05 |
2009-06-05 |
Takeda Pharmaceuticals Co |
Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
|
US8324395B2
(en)
|
2007-08-23 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
EP2184285B1
(fr)
|
2007-08-29 |
2015-11-04 |
Takeda Pharmaceutical Company Limited |
Composé hétérocyclique et son utilisation
|
HUE030774T2
(hu)
*
|
2007-09-06 |
2017-05-29 |
Boston Biomedical Inc |
Kinázinhibitorokból álló készítmények és felhasználásuk a rák és a kinázokhoz kapcsolódó más betegségek kezelésére
|
JP5393691B2
(ja)
*
|
2007-10-09 |
2014-01-22 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬(TpoRA)
|
AU2008340991B2
(en)
|
2007-12-21 |
2012-02-23 |
University Health Network |
Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
|
EP2225226B1
(fr)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Composés et leur utilisation dans un procédé pour le traitement du cancer
|
NZ587504A
(en)
|
2008-02-21 |
2012-09-28 |
Merck Sharp & Dohme |
Benzopyrazole derivatives as ERK inhibitors
|
CA2999321A1
(fr)
|
2008-07-17 |
2010-01-21 |
Critical Outcome Technologies Inc. |
Composes inhibiteurs et procedes de traitement du cance
|
ES2548141T3
(es)
|
2008-11-20 |
2015-10-14 |
Glaxosmithkline Llc |
Compuestos químicos
|
JP5579619B2
(ja)
|
2008-12-01 |
2014-08-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
KR101687841B1
(ko)
|
2008-12-09 |
2016-12-19 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체의 조절제
|
PE20120003A1
(es)
|
2009-01-30 |
2012-02-12 |
Glaxosmithkline Llc |
Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
|
WO2010100127A1
(fr)
|
2009-03-04 |
2010-09-10 |
Novartis Ag |
Dérivés d'imidazole disubstitués en tant que modulateurs de la protéine kinase raf
|
WO2010115279A1
(fr)
|
2009-04-06 |
2010-10-14 |
University Health Network |
Inhibiteurs de kinases et procédé de traitement du cancer avec ceux-ci
|
ES2638323T3
(es)
|
2009-05-20 |
2017-10-19 |
Glaxosmithkline Llc |
Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa
|
CA2771532C
(fr)
|
2009-08-17 |
2021-03-23 |
Intellikine, Inc. |
Composes heterocycliques et leurs utilisations
|
BR112012003653A2
(pt)
|
2009-08-21 |
2016-03-22 |
Smithkline Beecham Cork Ltd |
"método de tratar o câncer."
|
US20110065698A1
(en)
|
2009-08-26 |
2011-03-17 |
Cylene Pharmaceuticals, Inc. |
Novel protein kinase modulators
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
JP5763077B2
(ja)
|
2009-09-14 |
2015-08-12 |
ギリアード サイエンシーズ, インコーポレイテッド |
トール様受容体のモジュレーター
|
ME03497B
(fr)
|
2009-10-16 |
2020-04-20 |
Novartis Ag |
Combination comprenant un inhibiteur de MEK et un inhibiteur de B-raf
|
US8962652B2
(en)
|
2009-10-22 |
2015-02-24 |
Gilead Sciences, Inc. |
Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
|
WO2011057204A2
(fr)
*
|
2009-11-06 |
2011-05-12 |
The Johns Hopkins University |
Toxicité neuronale médiée par lrrk2
|
CN102770426B
(zh)
|
2010-02-05 |
2016-03-23 |
诺瓦提斯公司 |
作为蛋白激酶抑制剂的化合物和组合物
|
US8598156B2
(en)
|
2010-03-25 |
2013-12-03 |
Glaxosmithkline Llc |
Chemical compounds
|
EP2552915B1
(fr)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Composés pour le traitement du vih
|
SI2556071T1
(sl)
|
2010-04-06 |
2016-12-30 |
University Health Network |
Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
|
AU2011268906A1
(en)
|
2010-06-25 |
2013-01-31 |
Novartis Ag |
Heteroaryl compounds and compositions as protein kinase inhibitors
|
US20130172378A1
(en)
|
2010-09-14 |
2013-07-04 |
Glaxosmithkline Llc |
Combination of BRAF and VEGF Inhibitors
|
MX337662B
(es)
|
2010-10-06 |
2016-03-14 |
Glaxosmithkline Llc |
Derivados de bencimidazol como inhibidores de cinasa pi3.
|
GB201112607D0
(en)
|
2011-07-22 |
2011-09-07 |
Glaxo Group Ltd |
Novel compounds
|
TWI505828B
(zh)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產(第二)有限公司 |
新穎醫藥組成物
|
WO2012097021A1
(fr)
|
2011-01-11 |
2012-07-19 |
Glaxosmithkline Llc |
Combinaison
|
WO2012116237A2
(fr)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Composés hétérocycliques et leurs utilisations
|
RU2622015C2
(ru)
|
2011-11-11 |
2017-06-08 |
Новартис Аг |
Способ лечения пролиферативного заболевания
|
CA2856406C
(fr)
|
2011-11-23 |
2020-06-23 |
Novartis Ag |
Formulations pharmaceutiques
|
JP2015506955A
(ja)
|
2012-01-31 |
2015-03-05 |
スミスクライン ビーチャム (コーク) リミテッド |
がんを治療する方法
|
WO2013143597A1
(fr)
|
2012-03-29 |
2013-10-03 |
Glaxo Group Limited |
Inhibiteurs d'enzymes de déméthylase
|
BR112015011456A2
(pt)
|
2012-11-20 |
2017-07-11 |
Genentech Inc |
compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
|
KR102206432B1
(ko)
|
2012-11-30 |
2021-01-22 |
노파르티스 아게 |
신규 제약 조성물
|
RU2015132907A
(ru)
|
2013-01-09 |
2017-02-14 |
Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед |
Комбинация
|
JP6231129B2
(ja)
|
2013-01-10 |
2017-11-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
脂肪酸シンターゼ阻害剤
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
RU2015143526A
(ru)
*
|
2013-03-13 |
2017-04-19 |
Бостон Байомедикал, Инк. |
Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
WO2014195852A1
(fr)
|
2013-06-03 |
2014-12-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf
|
EP3052494B1
(fr)
|
2013-06-28 |
2018-12-26 |
H. Hoffnabb-La Roche Ag |
Composés d'azaindazole en tant qu'inhibiteurs de la t790m contenant des mutants de l'egfr
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
CA2925374A1
(fr)
|
2013-10-01 |
2015-04-09 |
Novartis Ag |
Combinaison
|
JP6355724B2
(ja)
|
2013-10-01 |
2018-07-11 |
ノバルティス アーゲー |
がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
|
WO2015056180A1
(fr)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Dérivés d'indoline utilisés comme inhibiteurs de perk
|
KR102195494B1
(ko)
|
2013-10-18 |
2020-12-28 |
유니버시티 헬스 네트워크 |
췌장암 치료
|
US20160367662A1
(en)
|
2013-12-12 |
2016-12-22 |
Novartis Ag |
Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
|
WO2015128837A1
(fr)
|
2014-02-26 |
2015-09-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Méthodes de traitement de patients atteints de cancer réagissant à l'inhibiteur d'ezh2 gsk126
|
RU2016139697A
(ru)
|
2014-03-12 |
2018-04-12 |
Новартис Аг |
Комбинация, содержащая ингибитор btk и ингибитор akt
|
WO2016001907A1
(fr)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
|
NZ728072A
(en)
|
2014-07-11 |
2018-06-29 |
Gilead Sciences Inc |
Modulators of toll-like receptors for the treatment of hiv
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
KR20190125537A
(ko)
|
2014-09-16 |
2019-11-06 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체 조정제의 고체 형태
|
WO2016055935A1
(fr)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combinaison d'inhibiteur de déméthylase 1 spécifique à la lysine et d'agoniste de thrombopoïétine
|
WO2016059602A2
(fr)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Méthodes de traitement du cancer et compositions associées
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
KR20180036996A
(ko)
|
2015-08-04 |
2018-04-10 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 치료 및 그의 용도 및 방법
|
US20180222989A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
WO2017021912A1
(fr)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Modulateurs de tlr combinés avec anticorps anti-ox40
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
RU2018107930A
(ru)
|
2015-08-06 |
2019-09-06 |
Глэксосмитклайн Байолоджикалз Са |
Агонисты tlr4, их композиции и применение для лечения рака
|
EP3331919A1
(fr)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Polythérapie comprenant des anticorps anti-ctla-4
|
BR112018011228A2
(pt)
|
2015-12-01 |
2019-01-15 |
Glaxosmithkline Ip Dev Ltd |
tratamentos de combinação e seus usos e métodos
|
EP3366691A1
(fr)
|
2015-12-03 |
2018-08-29 |
GlaxoSmithKline Intellectual Property Development Limited |
Dinucléotides cycliques de purine utilisés comme modulateurs de sting
|
WO2017098421A1
(fr)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Composés benzothiadiazine
|
WO2017153952A1
(fr)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
Dérivés de 5-sulfamoyl-2-hydroxybenzamide
|
MA43827A
(fr)
|
2016-03-18 |
2018-11-28 |
Immune Sensor Llc |
Composés di-nucléotides cycliques et leurs procédés d'utilisation
|
CA3019630A1
(fr)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Amides heterocycliques utiles en tant que modulateurs de proteine
|
AU2017247806B2
(en)
|
2016-04-07 |
2019-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
CA3031047A1
(fr)
|
2016-07-20 |
2018-01-25 |
Glaxosmithkline Intellectual Property Development Limited |
Derives d'isoquinoleine utilises comme inhibiteurs de perk
|
US11649289B2
(en)
|
2016-08-04 |
2023-05-16 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-ICOS and anti-PD-1 antibody combination therapy
|
EP3512842B1
(fr)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Dérivés d'indole en tant qu'agents de dégradation des récepteurs de l'estrogène
|
WO2018119441A1
(fr)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Molécules chimériques ciblant la protéolyse de l'egfr et procédés d'utilisation associés
|
IL294423B2
(en)
|
2016-12-23 |
2024-01-01 |
Univ Yale |
Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma
|
WO2018150326A1
(fr)
|
2017-02-15 |
2018-08-23 |
Glaxosmithkline Intellectual Property Development Limited |
Polythérapie pour le traitement du cancer
|
EP3648744A1
(fr)
|
2017-07-05 |
2020-05-13 |
Novartis AG |
Nouvelle composition pharmaceutique
|
WO2019021208A1
(fr)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
Dérivés d'indazole utiles en tant qu'inhibiteurs de perk
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
WO2019053617A1
(fr)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Composés chimiques
|
EP3692033A1
(fr)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih
|
JP7291130B2
(ja)
|
2017-10-05 |
2023-06-14 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
インターフェロン遺伝子の刺激物質(sting)の調節物質
|
WO2019106605A1
(fr)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Polythérapie pour le traitement du cancer
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
WO2020030570A1
(fr)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinaisons d'un anticorps ox40 et d'un modulateur de tlr4 et leurs utilisations
|
WO2020030571A1
(fr)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinaisons d'un anticorps pd-1 et d'un modulateur de tlr4 et leurs utilisations
|
WO2020029799A1
(fr)
*
|
2018-08-07 |
2020-02-13 |
Metagone Biotech Inc. |
Sels d'ammonium de 3-(3, 5-dibromo-4-hydroxybenzylidène)-5-indo -1,3-dihydroindol-2-one et leurs utilisations
|
KR20210080378A
(ko)
*
|
2018-09-18 |
2021-06-30 |
1글로브 바이오메디칼 씨오., 엘티디. |
비만의 치료
|
IL310831A
(en)
|
2018-11-30 |
2024-04-01 |
Glaxosmithkline Ip Dev Ltd |
Compounds useful in curing HIV
|
WO2020160365A1
(fr)
|
2019-02-01 |
2020-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotine en combinaison avec du pembrolizumab pour le traitement du cancer
|
JP2022533194A
(ja)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
|
EP3969438A1
(fr)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Dérivés d'acide oxoacridinyle acétique et procédés d'utilisation
|
MX2021015651A
(es)
|
2019-06-26 |
2022-06-14 |
Glaxosmithkline Ip Dev Ltd |
Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
WO2021043961A1
(fr)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et une chimiothérapie
|
WO2021046293A1
(fr)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et du trémélimumab
|
US20230067202A1
(en)
|
2020-01-28 |
2023-03-02 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
CN114573453A
(zh)
*
|
2020-12-02 |
2022-06-03 |
荆楚理工学院 |
一种选择性的羧酸酯裂解方法
|
CN117677398A
(zh)
|
2021-07-27 |
2024-03-08 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
KR102566028B1
(ko)
*
|
2021-08-10 |
2023-08-10 |
계명대학교 산학협력단 |
신규한 다중 단백질 키나아제 억제제
|
WO2023230541A1
(fr)
|
2022-05-27 |
2023-11-30 |
Viiv Healthcare Company |
Dérivés de pipérazine utiles dans le traitement du vih
|